company background image
VX1 logo

Vertex Pharmaceuticals DB:VX1 Stock Report

Last Price

€457.30

Market Cap

€119.9b

7D

5.3%

1Y

28.4%

Updated

06 Nov, 2024

Data

Company Financials +

Vertex Pharmaceuticals Incorporated

DB:VX1 Stock Report

Market Cap: €119.9b

VX1 Stock Overview

A biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).

VX1 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Risk Analysis

No risks detected for VX1 from our risk checks.

Vertex Pharmaceuticals Incorporated Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Vertex Pharmaceuticals
Historical stock prices
Current Share PriceUS$457.30
52 Week HighUS$475.90
52 Week LowUS$315.10
Beta0.40
11 Month Change11.62%
3 Month Change7.60%
1 Year Change28.44%
33 Year Change176.21%
5 Year Change143.87%
Change since IPO1,536.14%

Recent News & Updates

Recent updates

Shareholder Returns

VX1DE BiotechsDE Market
7D5.3%0.7%-1.3%
1Y28.4%-15.4%13.9%

Return vs Industry: VX1 exceeded the German Biotechs industry which returned -15.4% over the past year.

Return vs Market: VX1 exceeded the German Market which returned 13.9% over the past year.

Price Volatility

Is VX1's price volatile compared to industry and market?
VX1 volatility
VX1 Average Weekly Movement3.5%
Biotechs Industry Average Movement5.8%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.5%
10% least volatile stocks in DE Market2.3%

Stable Share Price: VX1 has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: VX1's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19895,400Reshma Kewalramaniwww.vrtx.com

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company’s pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial.

Vertex Pharmaceuticals Incorporated Fundamentals Summary

How do Vertex Pharmaceuticals's earnings and revenue compare to its market cap?
VX1 fundamental statistics
Market cap€119.93b
Earnings (TTM)-€446.98m
Revenue (TTM)€9.90b

12.0x

P/S Ratio

-265.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VX1 income statement (TTM)
RevenueUS$10.63b
Cost of RevenueUS$4.77b
Gross ProfitUS$5.86b
Other ExpensesUS$6.34b
Earnings-US$479.80m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.86
Gross Margin55.13%
Net Profit Margin-4.52%
Debt/Equity Ratio0%

How did VX1 perform over the long term?

See historical performance and comparison